342 related articles for article (PubMed ID: 19075702)
1. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses.
Sekijima Y; Kelly JW; Ikeda S
Curr Pharm Des; 2008; 14(30):3219-30. PubMed ID: 19075702
[TBL] [Abstract][Full Text] [Related]
2. Recent progress in the understanding and treatment of transthyretin amyloidosis.
Sekijima Y
J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
[TBL] [Abstract][Full Text] [Related]
3. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
4. Nearly 200 X-ray crystal structures of transthyretin: what do they tell us about this protein and the design of drugs for TTR amyloidoses?
Palaninathan SK
Curr Med Chem; 2012; 19(15):2324-42. PubMed ID: 22471981
[TBL] [Abstract][Full Text] [Related]
5. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses.
Johnson SM; Wiseman RL; Sekijima Y; Green NS; Adamski-Werner SL; Kelly JW
Acc Chem Res; 2005 Dec; 38(12):911-21. PubMed ID: 16359163
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
Green NS; Palaninathan SK; Sacchettini JC; Kelly JW
J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036
[TBL] [Abstract][Full Text] [Related]
7. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis.
Green NS; Foss TR; Kelly JW
Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14545-50. PubMed ID: 16195386
[TBL] [Abstract][Full Text] [Related]
8. Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
Connelly S; Mortenson DE; Choi S; Wilson IA; Powers ET; Kelly JW; Johnson SM
Bioorg Med Chem Lett; 2017 Aug; 27(15):3441-3449. PubMed ID: 28625364
[TBL] [Abstract][Full Text] [Related]
9. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology.
Sekijima Y; Hammarström P; Matsumura M; Shimizu Y; Iwata M; Tokuda T; Ikeda S; Kelly JW
Lab Invest; 2003 Mar; 83(3):409-17. PubMed ID: 12649341
[TBL] [Abstract][Full Text] [Related]
10. Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidoses.
Galant NJ; Bugyei-Twum A; Rakhit R; Walsh P; Sharpe S; Arslan PE; Westermark P; Higaki JN; Torres R; Tapia J; Chakrabartty A
Sci Rep; 2016 Apr; 6():25080. PubMed ID: 27122057
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and therapeutic approaches to transthyretin amyloidosis.
Ando Y; Ueda M
Curr Med Chem; 2012; 19(15):2312-23. PubMed ID: 22471980
[TBL] [Abstract][Full Text] [Related]
12. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis.
Sekijima Y; Dendle MA; Kelly JW
Amyloid; 2006 Dec; 13(4):236-49. PubMed ID: 17107884
[TBL] [Abstract][Full Text] [Related]
13. Interactions amongst plasma retinol-binding protein, transthyretin and their ligands: implications in vitamin A homeostasis and transthyretin amyloidosis.
Raghu P; Sivakumar B
Biochim Biophys Acta; 2004 Dec; 1703(1):1-9. PubMed ID: 15588697
[TBL] [Abstract][Full Text] [Related]
14. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.
Penchala SC; Connelly S; Wang Y; Park MS; Zhao L; Baranczak A; Rappley I; Vogel H; Liedtke M; Witteles RM; Powers ET; Reixach N; Chan WK; Wilson IA; Kelly JW; Graef IA; Alhamadsheh MM
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9992-7. PubMed ID: 23716704
[TBL] [Abstract][Full Text] [Related]
15. Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism.
Si JB; Kim B; Kim JH
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922648
[TBL] [Abstract][Full Text] [Related]
16. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis.
Tojo K; Sekijima Y; Kelly JW; Ikeda S
Neurosci Res; 2006 Dec; 56(4):441-9. PubMed ID: 17028027
[TBL] [Abstract][Full Text] [Related]
17. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.
Bulawa CE; Connelly S; Devit M; Wang L; Weigel C; Fleming JA; Packman J; Powers ET; Wiseman RL; Foss TR; Wilson IA; Kelly JW; Labaudinière R
Proc Natl Acad Sci U S A; 2012 Jun; 109(24):9629-34. PubMed ID: 22645360
[TBL] [Abstract][Full Text] [Related]
18. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants.
Miller SR; Sekijima Y; Kelly JW
Lab Invest; 2004 May; 84(5):545-52. PubMed ID: 14968122
[TBL] [Abstract][Full Text] [Related]
19. Specific disruption of transthyretin(105-115) fibrilization using "stabilizing" inhibitors of transthyretin amyloidogenesis.
Liang Y; Ore MO; Morin S; Wilson DJ
Biochemistry; 2012 Apr; 51(16):3523-30. PubMed ID: 22482799
[TBL] [Abstract][Full Text] [Related]
20. Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: implications for transthyretin amyloidosis.
Wiseman RL; Green NS; Kelly JW
Biochemistry; 2005 Jun; 44(25):9265-74. PubMed ID: 15966751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
